Skip to main content

Table 4 Analgesic use according to the experience of bone complications

From: Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

Outcome At-risk perioda Patient population EU5b
N = 813
France
N = 146
Germany
N = 175
Italy
N = 173
Spain
N = 141
UK
N = 173
Patients who received analgesics by at-risk period, n (%)c
 Any analgesic use Overall All patients 461 (57) 102 (70) 110 (63) 84 (49) 94 (67) 66 (38)
With BCs 162 (76) 36 (90) 34 (71) 35 (71) 25 (86) 27 (63)
Without BCs 299 (50) 66 (62) 76 (60) 49 (40) 69 (62) 39 (30)
Period 2 All patients 457 (56) 104 (71) 110 (63) 84 (49) 93 (66) 60 (35)
With BCs 160 (75) 34 (85) 35 (73) 33 (67) 26 (90) 28 (65)
Without BCs 296 (49) 70 (66) 75 (59) 51 (41) 67 (60) 32 (25)
Period 3 All patients 234 (29) 43 (30) 66 (38) 46 (27) 10 (7) 32 (19)
With BCs 89 (42) 15 (38) 21 (44) 22 (45) 21 (72) 13 (30)
Without BCs 145 (24) 28 (26) 45 (35) 24 (19) 31 (28) 19 (15)
Patients who received analgesics by stepc and at-risk period, n (%)d
 Step 1 Overall All patients 255 (31) 38 (26) 70 (40) 56 (32) 51 (36) 47 (27)
 Step 2 192 (24) 46 (32) 50 (29) 30 (17) 36 (26) 25 (15)
 Step 3 162 (20) 51 (35) 37 (21) 21 (12) 34 (24) 10 (6)
 Step 1 With BCs 73 (34) 11 (28) 18 (38) 21 (43) 9 (31) 14 (33)
 Step 2 72 (34) 15 (38) 11 (23) 16 (33) 12 (41) 16 (37)
 Step 3 72 (34) 21 (53) 18 (38) 10 (20) 12 (41) 7 (16)
 Step 1 Without BCs 182 (30) 27 (26) 52 (41) 35 (28) 42 (38) 33 (25)
 Step 2 120 (20) 31 (29) 39 (31) 14 (11) 24 (21) 9 (7)
 Step 3 89 (15) 30 (28) 19 (15) 11 (9) 22 (20) 3 (2)
 Step 1 Period 2 All patients 216 (27) 30 (21) 63 (36) 50 (29) 36 (26) 41 (24)
 Step 2 165 (20) 39 (27) 49 (28) 23 (13) 31 (22) 19 (11)
 Step 3 144 (18) 46 (32) 33 (19) 18 (10) 32 (23) 8 (5)
 Step 1 With BCs 65 (30) 8 (20) 16 (33) 18 (37) 8 (28) 16 (37)
 Step 2 62 (29) 14 (35) 12 (25) 12 (24) 9 (31) 13 (30)
 Step 3 59 (28) 16 (40) 16 (33) 7 (14) 11 (38) 6 (14)
 Step 1 Without BCs 150 (25) 22 (21) 47 (37) 32 (26) 28 (25) 25 (19)
 Step 2 102 (17) 25 (24) 37 (29) 11 (9) 22 (20) 6 (5)
 Step 3 86 (14) 30 (28) 17 (13) 11 (9) 21 (19) 2 (2)
 Step 1 Period 3 All patients 130 (16) 17 (12) 39 (22) 30 (17) 52 (37) 21 (12)
 Step 2 82 (10) 14 (10) 27 (15) 15 (9) 30 (21) 13 (8)
 Step 3 56 (7) 15 (10) 17 (10) 7 (4) 13 (9) 5 (3)
 Step 1 With BCs 40 (19) 5 (13) 9 (19) 15 (31) 7 (24) 6 (14)
 Step 2 33 (15) 3 (8) 8 (17) 8 (16) 8 (28) 8 (19)
 Step 3 33 (16) 3 (8) 8 (17) 4 (8) 7 (24) 4 (9)
 Step 1 Without BCs 90 (15) 12 (11) 30 (24) 15 (12) 23 (21) 15 (12)
 Step 2 49 (8) 11 (10) 19 (15) 7 (6) 5 (5) 5 (4)
 Step 3 23 (4) 6 (6) 9 (7) 3 (2) 3 (3) 1 (1)
  1. BCs bone complications, EU5 five European countries (France, Germany, Italy, Spain and the UK), UK United Kingdom
  2. aOverall: from multiple myeloma diagnosis to disease progression following first-line treatment; period 2: during active first-line therapy; period 3: after treatment discontinuation. Note that analgesic use was not recorded for period 1 (before initiation of induction therapy)
  3. bAggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total
  4. cStep on the World Health Organization analgesic ladder
  5. dExpressed as a percentage of the total number of patients, patients with BCs or patients without BCs, as indicated (patient numbers by country – EU5 with BCs: 214; EU5 without BCs: 599; France with BCs: 40; France without BCs: 106; Germany with BCs: 48; Germany without BCs: 127; Italy with BCs: 49; Italy without BCs: 124; Spain with BCs: 29; Spain without BCs: 112; UK with BCs: 43; UK without BCs: 130)